Objective: To examine the effects of RS on serum cholesterol and expression of genes associated with cholesterol metabolism in rat liver for understanding its mechanism. Method: Eighteen rats were randomly assigned to three groups, six rats each. They were fed with chemical purified normal diet (control group), low RS (15%Hi-maize 1043) diet and high RS (30%Hi-maize 1043) diet respectively. Six weeks later, serum cholesterol and short chain fatty acid (SCFA) in the cecum were measured. Likewise, hepatic cholesterol 7?-hydroxylase, LDL receptor, and SR-B1 mRNA levels were measured by realtime PCR. Results: Hepatic cholesterol 7a-hydroxylase, LDL receptor, SR-B1 mRNA levels and cecal acetate, propionate and n-butyrate concentrations in the high RS group were significantly higher than those in the control group (P

Objective To investigate the combined use of osteoarthritis treatment effect of lornoxicam and peptide drugs.Methods 260 patients with osteoarthritis treated in our hospital from May 2014 to June 2016 were selected, were randomly divided into study group and control group, each group of 130 cases.The patients in the control group were treated with sodium hyaluronate and lornoxicam, the study group was given bone peptide on the basis of the control group. The pain scores, knee function and adverse reactions were compared between the two groups.Results There was no significant difference in VAS and WOMAC scores between the two groups before treatment; after treatment, the improvement of VAS and WOMAC score in the study group was better than that in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion Sodium hyaluronate, bone peptide, lornoxicam and other drugs in the treatment of patients with osteoarthritis clinical efficacy is obvious, and fewer adverse reactions.

The article reviewed the research progress of ligustilide in recent years and elaborated its pharmacological functions and mechanisms in detail,especially in ischemic brain injury.Its mechanism includes reducing cerebral infarct volumes and improving neurobehavioral deficits,anti-oxidant and anti-apoptosis,antithrombotic activity,calcium channel blockers function,and effect on erythropoietin.Other pharmacological effects of ligustilide including inhibiting vascular smooth muscle cell proliferation,anti-inflammatory and analgesic effects,effects on LPS-induced endotoxic shock,inhibiting constriction effect,suppression of the central nervous system,and ameliorating the memory impairment induced by scopolamine and so on,are also introduced.Ligustilide has potential pharmacological value,which provides a reference for its further research and development.

Objective Toinvestigatethethrombusclinicalcurativeeffectandpracticalvalueintreatmentofdeepveinthrombosis (DVT)byusingmodifiedaspirationcatheter.Methods Atotalof35patientswhometthediagnosticcriteriaofDVTwererandomly assignedintoexperimentalandcontrolgroups.Afterasufficientpreoperativepreparation,thepatientsweredividedintotheexperimentalgroup (n=18,usingmodifiedaspirationcatheterwithsubsequenturokinasethrombolysisandconventionalanticoagulationtherapy)andthe controlgroup [n=17,usingthe8Fvascularsheaths (COOK,USA)duringtheprocedure,subsequenturokinasethrombolysisand conventionalanticoagulationtherapy].Thepatencyofvessels,theperimeterdifferenceandthecomplicationweredocumented.Theresultswere comparedbetweenthetwogroups.Results Inexperimentalgroup,thrombusremovalofgradeⅣ (removalratelessthan0%)was 0%in0case,gradeⅢ (removalratelessthan50%)was5.56%in1case,gradeⅡ (removalrategreaterthan50%)was94.44%in ncontrolgroup,thrombusremovalofgradeⅣwas23.53%in4cases,gradeⅢwas52.94%in9cases,gradeⅡwas23.53%in4cases. Thedifferencesofthelegcircumferenceoftheaffectedextremitiesat15cmaboveandbelowthekneejointattimeofdischargewere alllessthanthoseatadmission.Thedifferencesinbothpreoperativeandpostoperativedatabetweenthetwogroupswerestatistically significant(bothP<0.05).Noseriouscomplicationswerefoundintwogroups.Conclusion UsingmodifiedaspirationcathetertreatingDVTisa safeandeffectivemethod,whichhashighsuctionefficiencyandfewcomplications.Therefore,itisworthytoberecommended. 17casesI.

Objective To explore the clinical application of a new laryngeal mask in implantation of tracheal stent.Methods The new laryngeal masks were implanted under general anesthesia for 20 patients with tracheal or primary bronchus stenosis.The oxygen was continuously supplied from its side hole,and the stents were subsequently implanted from the tail hole.Results By using the new laryngeal masks under general anesthesia,all of 20 patients were successfully and leisurely implanted the tracheal stent.After the operation,the dyspnea symptoms were significantly improved,and there was no complication.Conclusion Stent implantation by using the new laryngeal mask under general anesthesia will provide a safe and effective treatment for tracheal stenosis.

[This corrects the article DOI: 10.1016/j.apsb.2021.08.015.].

Osteosarcoma is a kind of bone tumor with highly proliferative and invasive properties, a high incidence of pulmonary metastasis and a poor prognosis. Chemotherapy is the mainstay of treatment for osteosarcoma. Currently, there are no molecular targeted drugs approved for osteosarcoma treatment, particularly effective drugs for osteosarcoma with pulmonary metastases. It has been reported that fibroblast activation protein alpha (FAPα) is upregulated in osteosarcoma and critically associated with osteosarcoma progression and metastasis, demonstrating that FAPα-targeted agents might be a promising therapeutic strategy for osteosarcoma. In the present study, we reported that the FAPα-activated vinblastine prodrug Z-GP-DAVLBH exhibited potent antitumor activities against FAPα-positive osteosarcoma cells in vitro and in vivo. Z-GP-DAVLBH inhibited the growth and induced the apoptosis of osteosarcoma cells. Importantly, it also decreased the migration and invasion capacities and reversed epithelial-mesenchymal transition (EMT) of osteosarcoma cells in vitro and suppressed pulmonary metastasis of osteosarcoma xenografts in vivo. Mechanistically, Z-GP-DAVLBH suppressed the AXL/AKT/GSK-3β/β-catenin pathway, leading to inhibition of the growth and metastatic spread of osteosarcoma cells. These findings demonstrate that Z-GP-DAVLBH is a promising agent for the treatment of FAPα-positive osteosarcoma, particularly osteosarcoma with pulmonary metastases.